systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-448Research ArticleКАРДИОЛОГИЯ / CARDIOLOGYМесто b-адреноблокаторов в лечении артериальной гипертонии, согласно мнению российских и европейских экспертовThe role of b-blockers in treatment of hypertension, according to Russian and European expertsОстроумоваО. Д.OstroumovaO. D.ostroumova.olga@mail.ruФоминаВ. М.FominaV. M.noemail@neicon.ruЩукинаГ. Н.ShchukinaG. N.noemail@neicon.ruСмолярчукЕ. А.SmoliarchukE. A.noemail@neicon.ruГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России; ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава РоссииРоссияA.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation; I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian FederationRussian FederationГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава РоссииРоссияA.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian FederationRussian FederationГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава РоссииРоссияI.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian FederationRussian Federation201623122022131610Copyright © Остроумова О.Д., Фомина В.М., Щукина Г.Н., Смолярчук Е.А., 20222022Остроумова О.Д., Фомина В.М., Щукина Г.Н., Смолярчук Е.А.Ostroumova O.D., Fomina V.M., Shchukina G.N., Smoliarchuk E.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/448

В статье рассмотрены вопросы применения b-адреноблокаторов (b-АБ) для лечения артериальной гипертонии (АГ). Приведены положения современных российских и европейских рекомендаций о месте b-АБ в лечении АГ, в том числе об их преимуществах при сочетании АГ с ишемической болезнью сердца, хронической сердечной недостаточностью, фибрилляцией предсердий. Подробно проанализированы эффективность и безопасность b-АБ при сахарном диабете, метаболическом синдроме, дислипидемии, поражении периферических артерий, хронической обструктивной болезни легких, половой дисфункции, у лиц разного возраста и пола. Подчеркивается, что выбор b-АБ внутри класса должен определяется его селективностью, изученностью в клинических исследованиях, особенностями фармакокинетики. Приведены данные об эффективности и безопасности применения метопролола сукцината.

The article focuses on the use of b-blockers for the treatment of arterial hypertension (AH). Given the situation of modern Russian and European recommendations about the place of b-blockers in the treatment of AH, including their benefits with a combination of hypertension with coronary heart disease, chronic heart failure, atrial fibrillation. Analyzed the efficacy and safety of b-blockers in diabetes mellitus, metabolic syndrome, dyslipidemia, peripheral artery, chronic obstructive pulmonary disease, sexual dysfunction, in individuals of different age and gender. It is emphasized that the selection of b-blockers inside of a class is determined by its selectivity, the study in clinical studies, pharmacokinetic characteristics. Data about efficiency and safety of application of metoprolol succinate.

артериальная гипертонияантигипертензивная терапияметопролола сукцинат-адреноблокаторыarterial hypertensionantihypertensive therapyb-blockersmetoprolol succinateReferencesWiyonge C.S, Bradley H.A, Volmink J et al. Cochrane Database Syst Rev 2012; 11: CD002003.doi.Wiyonge C.S, Bradley H.A, Volmink J et al. Cochrane Database Syst Rev 2012; 11: CD002003.doi.Bradley H.A, Wiyonge CS, Volmink V.A et al. How strong is the evidence for use of beta - blockers as first line therapy for hypertension? J Hypertens 2006; 24: 2131-41.Bradley H.A, Wiyonge CS, Volmink V.A et al. How strong is the evidence for use of beta - blockers as first line therapy for hypertension? J Hypertens 2006; 24: 2131-41.Law M.R, Morris J.K, Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta - analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.Law M.R, Morris J.K, Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta - analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood pressure - lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165: 1410-9.Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood pressure - lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165: 1410-9.Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood pressure - lowering regimens on major cardiovascular events: results of prospectively designed overviews ofrandomised trials. Lancet 2003; 362: 1527-35.Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood pressure - lowering regimens on major cardiovascular events: results of prospectively designed overviews ofrandomised trials. Lancet 2003; 362: 1527-35.Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281-357.Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281-357.Диагностика и лечение артериальной гипертензии (Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов) // Системные гипертензии. 2010; 7 (3): 5-26.Диагностика и лечение артериальной гипертензии (Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов) // Системные гипертензии. 2010; 7 (3): 5-26.Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Кардиологич. вестн. 2015; 1.Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Кардиологич. вестн. 2015; 1.Клиническая фармакология. Под ред. В.Г.Кукеса. Изд. 4-е. М.: ГЭОТАР-Медиа, 2008; с. 392-5.Клиническая фармакология. Под ред. В.Г.Кукеса. Изд. 4-е. М.: ГЭОТАР-Медиа, 2008; с. 392-5.Yusuf S, Hawken S, Ounpuu S et al. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case - control study. Lancet 2004; 364: 937-52.Yusuf S, Hawken S, Ounpuu S et al. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case - control study. Lancet 2004; 364: 937-52.Mancia G, Laurent S, Agabiti-Rosei E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121-58.Mancia G, Laurent S, Agabiti-Rosei E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121-58.Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens 2009; 27: 923-34.Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens 2009; 27: 923-34.Кириченко А.А. Ишемическая болезнь сердца и контроль частоты сердечных сокращений // Consilium Medicum. 2015; 17 (5): 23-5.Кириченко А.А. Ишемическая болезнь сердца и контроль частоты сердечных сокращений // Consilium Medicum. 2015; 17 (5): 23-5.Tocci G, Sciarretta S, Volpe M. Development of heart failure in recent hypertension trials. J Hypertens 2008; 26: 1477-86.Tocci G, Sciarretta S, Volpe M. Development of heart failure in recent hypertension trials. J Hypertens 2008; 26: 1477-86.Beckett N.S, Peters R, Fletcher A.E et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887-98.Beckett N.S, Peters R, Fletcher A.E et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887-98.Mc Murray J.J.V, Adamopoulos S, Anker S.D et al. ESC Guidelines for diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2012; 33: 1787-847.Mc Murray J.J.V, Adamopoulos S, Anker S.D et al. ESC Guidelines for diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2012; 33: 1787-847.Rutten F.H, Zuithoff N.P, Halk F et al. Beta-Blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010; 170: 880-7.Rutten F.H, Zuithoff N.P, Halk F et al. Beta-Blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010; 170: 880-7.MERIT-HF Study Group. Effects of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized International Trial in Congestive Heart Failure (MERIT- HF). Lancet 1999; 353 (9169): 2001-7.MERIT-HF Study Group. Effects of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized International Trial in Congestive Heart Failure (MERIT- HF). Lancet 1999; 353 (9169): 2001-7.Wikstrand J, Hjalmarson A, Waagstein F et al. MERIT-HF Study Group. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). J Am Coll Cardiol 2002; 40 (3): 491-8.Wikstrand J, Hjalmarson A, Waagstein F et al. MERIT-HF Study Group. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). J Am Coll Cardiol 2002; 40 (3): 491-8.Camm A.J, Kirchhof P, Lip G.Y et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-429.Camm A.J, Kirchhof P, Lip G.Y et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-429.Camm A.J, Lip G.Y, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Eur Heart J 2012; 33: 2719-3274.Camm A.J, Lip G.Y, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Eur Heart J 2012; 33: 2719-3274.Sandberg A, Blomqvist I, Jonsson U.E, Lundborg P. Pharmacokinetic and pharmacodynamic properties of a new controlled - release formulation of metoprolol: A comparison with conventional tablets. Eur J Clin Pharmacol 1988; 33 (Suppl.): S9.Sandberg A, Blomqvist I, Jonsson U.E, Lundborg P. Pharmacokinetic and pharmacodynamic properties of a new controlled - release formulation of metoprolol: A comparison with conventional tablets. Eur J Clin Pharmacol 1988; 33 (Suppl.): S9.Oosterhuis B, Jonkman J, Zuiderwijk P, Sollie F. A pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK with a conventional slow release preparation. J Clin Pharmacol 1990; 30: S33-S38.Oosterhuis B, Jonkman J, Zuiderwijk P, Sollie F. A pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK with a conventional slow release preparation. J Clin Pharmacol 1990; 30: S33-S38.Sandberg A, Abrahamsson B, Regardh C-G et al. Pharmacokinetic and biopharmaceutic aspects of once daily treatment with metoprolol CR/ZOK: a review article. J Clin Pharmacol 1990; 30: S2-S16.Sandberg A, Abrahamsson B, Regardh C-G et al. Pharmacokinetic and biopharmaceutic aspects of once daily treatment with metoprolol CR/ZOK: a review article. J Clin Pharmacol 1990; 30: S2-S16.Lee Y-T, Liau C-S, Wong E.C.K et al. Pharmacokinetic and pharmacodynamic comparison of conventional and controlled release formulation of metoprolol in healthy Chinese subjects. Cardiovasc Drugs Ther 1989; 3 (4): 529-33.Lee Y-T, Liau C-S, Wong E.C.K et al. Pharmacokinetic and pharmacodynamic comparison of conventional and controlled release formulation of metoprolol in healthy Chinese subjects. Cardiovasc Drugs Ther 1989; 3 (4): 529-33.Lucker P, Moore G, Wiselgren I et al. Pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK once daily with conventional tablets once daily and in divided doses. J Clin Pharmacol 1990; 30 (Suppl.): S17-S27.Lucker P, Moore G, Wiselgren I et al. Pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK once daily with conventional tablets once daily and in divided doses. J Clin Pharmacol 1990; 30 (Suppl.): S17-S27.Wieselgren I, Lundborg P, Sandberg A et al. Pharmacokinetic and pharmacodynamic evaluation of metoprolol controlled release (CR/ZOK) 50 mg in young subjects. J Clin Pharmacol 1990; 30: S28-S32.Wieselgren I, Lundborg P, Sandberg A et al. Pharmacokinetic and pharmacodynamic evaluation of metoprolol controlled release (CR/ZOK) 50 mg in young subjects. J Clin Pharmacol 1990; 30: S28-S32.Kronig B. Hertz Kreislauf 1990; 22: 224-9.Kronig B. Hertz Kreislauf 1990; 22: 224-9.Nasr I.A, Bouzamondo A, Hulot J.S et al. Prevention of atrial fibrillation onset by beta - blocker treatment in heart failure: a meta - analysis. Eur Heart J 2007; 28: 457-62.Nasr I.A, Bouzamondo A, Hulot J.S et al. Prevention of atrial fibrillation onset by beta - blocker treatment in heart failure: a meta - analysis. Eur Heart J 2007; 28: 457-62.Swedberg K, Zannad F, Mc Murray J.J et al, EMPHASISHF Study Investigators. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHA- SISHF (Eplerenone in Mild Patients Hospitalization And SurvIvalStudy in Heart Failure) study. J Am Coll Cardiol 2012; 59: 1598-603.Swedberg K, Zannad F, Mc Murray J.J et al, EMPHASISHF Study Investigators. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHA- SISHF (Eplerenone in Mild Patients Hospitalization And SurvIvalStudy in Heart Failure) study. J Am Coll Cardiol 2012; 59: 1598-603.Schaer B.A, Schneider C, Jick S.S et al. Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: a nested case - control study. Ann Intern Med 2010; 152: 78-84.Schaer B.A, Schneider C, Jick S.S et al. Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: a nested case - control study. Ann Intern Med 2010; 152: 78-84.Schmieder R.E, Hilgers K.F, Schlaich M.P, Schmidt B.M. Renin - angiotensin system and cardiovascular risk. Lancet 2007; 369: 1208-19.Schmieder R.E, Hilgers K.F, Schlaich M.P, Schmidt B.M. Renin - angiotensin system and cardiovascular risk. Lancet 2007; 369: 1208-19.MERIT-HF Study Group. Effect of controlled - release metoprolol on total mortality, hospitalizations, and well - being in patients with heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure. MERIT-HF Study Group. JAMA 2000; 283: 1295-302.MERIT-HF Study Group. Effect of controlled - release metoprolol on total mortality, hospitalizations, and well - being in patients with heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure. MERIT-HF Study Group. JAMA 2000; 283: 1295-302.Elliott W, Meyer P.M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta - analysis. Lancet 2007; 369: 201-7.Elliott W, Meyer P.M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta - analysis. Lancet 2007; 369: 201-7.Paravastu S.C, Mendonca D.A, da Silva A. Beta blockers for peripheral arterial disease. Eur J Vasc Endovasc Surg 2009; 38: 66-70.Paravastu S.C, Mendonca D.A, da Silva A. Beta blockers for peripheral arterial disease. Eur J Vasc Endovasc Surg 2009; 38: 66-70.Radack K, Deck C. Beta - adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta - analysis of randomized controlled trials. Arch Intern Med 1991; 151: 1769-76.Radack K, Deck C. Beta - adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta - analysis of randomized controlled trials. Arch Intern Med 1991; 151: 1769-76.Camsari A, Arikan S, Avan C et al. Metoprolol, a beta-1 selective blocker, can be used safely in coronary artery disease patients with chronic obstructive pulmonary disease. Heart Vessels 2003; 18: 188-92.Camsari A, Arikan S, Avan C et al. Metoprolol, a beta-1 selective blocker, can be used safely in coronary artery disease patients with chronic obstructive pulmonary disease. Heart Vessels 2003; 18: 188-92.Hedblad B, Wikstrand J, Jabzon L et al. Low dose metoprolol CR/XL and fluvastatin slow progression of carotid intima - media thickness: main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 2001; 103: 1721-6.Hedblad B, Wikstrand J, Jabzon L et al. Low dose metoprolol CR/XL and fluvastatin slow progression of carotid intima - media thickness: main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 2001; 103: 1721-6.Wiklund O, Hulthe J, Wikstrand J et al. Effect of controlled release/extended release metoprolol on carotid intima - media thickness in patients with hypercholesterolemia: a 3-year randomized study. Stroke 2002; 33 (2): 572-7.Wiklund O, Hulthe J, Wikstrand J et al. Effect of controlled release/extended release metoprolol on carotid intima - media thickness in patients with hypercholesterolemia: a 3-year randomized study. Stroke 2002; 33 (2): 572-7.Franzen D, Metha A, Seifert N et al. Effects of beta - blockers on sexual performance in men with coronary heart disease. A prospective, randomized and double blinded study. Int J Impot Res 2001; 13: 348-51.Franzen D, Metha A, Seifert N et al. Effects of beta - blockers on sexual performance in men with coronary heart disease. A prospective, randomized and double blinded study. Int J Impot Res 2001; 13: 348-51.Blood Pressure Lowering Treatment Trialists’ Collaboration. Do men and women respond differently to blood pressure - lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J 2008; 29: 2669-80.Blood Pressure Lowering Treatment Trialists’ Collaboration. Do men and women respond differently to blood pressure - lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J 2008; 29: 2669-80.Coope J, Warrender T.S. Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ 1986; 293: 1145-51.Coope J, Warrender T.S. Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ 1986; 293: 1145-51.Dahlof B, Lindholm L.H, Hansson L et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338: 1281-5.Dahlof B, Lindholm L.H, Hansson L et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338: 1281-5.Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: metaanalysis of randomized trials. BMJ 2008; 336: 1121-3.Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: metaanalysis of randomized trials. BMJ 2008; 336: 1121-3.

The authors declare that there are no conflicts of interest present.